Ribociclib + Nonsteroidal Aromatase Inhibitor Benefits Early Breast Cancer

THURSDAY, March 21, 2024 -- Ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) significantly improves invasive disease-free survival among patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news